These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7534423)

  • 1. Effects of raclopride treatment on plasma and CSF HVA: relationships with clinical improvement in male schizophrenics.
    Csernansky JG; Newcomer JW; Jackson K; Lombrozo L; Faull KF; Zipursky R; Pfefferbaum A; Faustman WO
    Psychopharmacology (Berl); 1994 Nov; 116(3):291-6. PubMed ID: 7534423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF.
    Nikisch G; Baumann P; Wiedemann G; Kiessling B; Weisser H; Hertel A; Yoshitake T; Kehr J; Mathé AA
    J Clin Psychopharmacol; 2010 Oct; 30(5):496-503. PubMed ID: 20814316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melperone in the treatment of schizophrenia.
    Bjerkenstedt L
    Acta Psychiatr Scand Suppl; 1989; 352():35-9. PubMed ID: 2479227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia.
    Pickar D; Breier A; Hsiao JK; Doran AR; Wolkowitz OM; Pato CN; Konicki PE; Potter WZ
    Arch Gen Psychiatry; 1990 Jul; 47(7):641-8. PubMed ID: 1694425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment.
    Kahn RS; Davidson M; Knott P; Stern RG; Apter S; Davis KL
    Arch Gen Psychiatry; 1993 Aug; 50(8):599-605. PubMed ID: 7688208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics.
    Hsiao JK; Colison J; Bartko JJ; Doran AR; Konicki PE; Potter WZ; Pickar D
    Arch Gen Psychiatry; 1993 Aug; 50(8):606-14. PubMed ID: 7688209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationships between drug concentrations in serum and CSF, clinical effects and monoaminergic variables in schizophrenic patients treated with sulpiride or chlorpromazine.
    Alfredsson G; Bjerkenstedt L; Edman G; Härnryd C; Oxenstierna G; Sedvall G; Wiesel FA
    Acta Psychiatr Scand Suppl; 1984; 311():49-74. PubMed ID: 6199949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics.
    Kim YK; Kim L; Lee MS
    Schizophr Res; 2000 Sep; 44(3):165-75. PubMed ID: 10962218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma and CSF HVA before and after pharmacological treatment.
    Sharma R; Javaid JI; Janicak P; Faull K; Comaty J; Davis JM
    Psychiatry Res; 1989 Apr; 28(1):97-104. PubMed ID: 2740469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal.
    van Kammen DP; Peters J; van Kammen WB; Nugent A; Goetz KL; Yao J; Linnoila M
    Biol Psychiatry; 1989 Jun; 26(2):176-88. PubMed ID: 2472177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gamma-hydroxybutyrate in the treatment of schizophrenia.
    Levy MI; Davis BM; Mohs RC; Trigos GC; Mathé AA; Davis KL
    Psychiatry Res; 1983 May; 9(1):1-8. PubMed ID: 6193548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of mianserin on negative symptoms in schizophrenia.
    Mizuki Y; Kajimura N; Imai T; Suetsugi M; Kai S; Kaneyuki H; Yamada M
    Int Clin Psychopharmacol; 1990 Apr; 5(2):83-95. PubMed ID: 1696292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis.
    Mazure CM; Nelson JC; Jatlow PI; Bowers MB
    Biol Psychiatry; 1991 Sep; 30(5):475-82. PubMed ID: 1932395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind comparison of raclopride and haloperidol in the acute phase of schizophrenia. The British Isles Raclopride Study Group.
    Acta Psychiatr Scand; 1992 Nov; 86(5):391-8. PubMed ID: 1485530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Striatal dopamine metabolism increases during long-term haloperidol administration in rats but shows tolerance in response to acute challenge with raclopride.
    See RE
    Neurosci Lett; 1991 Aug; 129(2):265-8. PubMed ID: 1720879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates.
    Breslin NA; Suddath RL; Bissette G; Nemeroff CB; Lowrimore P; Weinberger DR
    Schizophr Res; 1994 Apr; 12(1):35-41. PubMed ID: 7517175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma homovanillic acid in neuroleptic responsive and nonresponsive schizophrenics.
    Duncan E; Wolkin A; Angrist B; Sanfilipo M; Wieland S; Cooper TB; Rotrosen J
    Biol Psychiatry; 1993 Oct; 34(8):523-8. PubMed ID: 8274579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERPs in schizophrenia: effects of antipsychotic medication.
    Ford JM; White PM; Csernansky JG; Faustman WO; Roth WT; Pfefferbaum A
    Biol Psychiatry; 1994 Aug; 36(3):153-70. PubMed ID: 7948453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
    Davidson M; Kahn RS; Knott P; Kaminsky R; Cooper M; DuMont K; Apter S; Davis KL
    Arch Gen Psychiatry; 1991 Oct; 48(10):910-3. PubMed ID: 1929760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychotic patients with increased plasma HVA and MHPG or increased HVA alone.
    Bowers MB
    Biol Psychiatry; 1993 Oct; 34(8):584-6. PubMed ID: 8274591
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.